Engineered elastin-like polypeptides: An efficient platform for enhanced cancer treatment

Drug delivery systems (DDSs) have recently gained widespread attention for improving drug loading and delivery efficiency in treating many cancers. Elastin-like polypeptides (ELPs) are synthetic peptides derived from a precursor of elastin (tropoelastin), reserving similar structural and physicochem...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 1113079
Main Authors Jiang, Aiguo, Guan, Xinqiang, He, Lianping, Guan, Xingang
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.01.2023
Subjects
cancer therapy
drug delivery
elastin-like polypeptide
inverse transition cycling
nanoparticle
Pharmacology
cancer therapy
nanoparticle
drug delivery
inverse transition cycling
elastin-like polypeptide
Online AccessGet full text

Cover

More Information
Summary:Drug delivery systems (DDSs) have recently gained widespread attention for improving drug loading and delivery efficiency in treating many cancers. Elastin-like polypeptides (ELPs) are synthetic peptides derived from a precursor of elastin (tropoelastin), reserving similar structural and physicochemical properties. ELPs have gained a variety of applications in tissue engineering and cancer therapy due to their excellent biocompatibility, complete degradability, temperature-responsive property, controllable sequence and length, and precisely tuned structure and function. ELPs-based drug delivery systems can improve the pharmacokinetics and biodistribution of therapeutic reagents, leading to enhanced antitumor efficacy. In this review, we summarize the recent application of ELPs in cancer treatment, focusing on the delivery of functional peptides, therapeutic proteins, small molecule drugs, and photosensitizers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Xuefang Hao, Inner Mongolia University for Nationalities, China
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Edited by: Yuxia Tang, First Affiliated Hospital, Nanjing Medical University, China
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.1113079